Introduction {#Sec1}
============

Chronic pancreatitis (CP) is a disabling inflammatory disease of the pancreas characterized by severe recurrent or continuous abdominal pain and considerable impact on the quality of life \[[@CR1]--[@CR4]\]. Patients with CP usually develop endocrine and exocrine insufficiency during the course of the disease as a result of the progressive loss of pancreatic parenchyma.

There is lack of international consensus regarding the initial diagnosis of CP, particularly at its early stages. The diagnosis is often made by a combination of clinical symptoms (e.g. abdominal pain, malabsorption, diabetes mellitus), pancreatic function tests (e.g. fecal elastase-1) and morphological abnormalities seen on imaging (e.g. calcifications, ductal lesions, pseudocysts) \[[@CR5], [@CR6]\]. Imaging plays a key role in the diagnosis and therapeutic management of patients with CP. The most frequently used imaging modalities for CP are endoscopic ultrasonography (EUS), endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance imaging (MRI), computed tomography (CT) and ultrasonography (US).

The aim of this meta-analysis was to determine the diagnostic accuracy of imaging modalities for the initial diagnostic assessment of CP.

Methods {#Sec2}
=======

Search {#Sec3}
------

A search was performed in Cochrane Library, MEDLINE, EMBASE and CINAHL databases, without restrictions for publication date or language up to September 2016. The search included terms for chronic pancreatitis, EUS, ERCP, MR imaging, CT and US. For detailed search details, see Appendix Table [5](#Tab5){ref-type="table"}.

Selection of studies {#Sec4}
--------------------

All search hits were screened on title and abstract and eligible articles on full text by two reviewers independently (YI and MAK). Disagreements were solved through discussion with a third reviewer (MAB). Studies were eligible when EUS, ERCP, MR imaging, CT or US was evaluated in patients with suspected CP. Duplicates, reviews, letters, case reports and book chapters were excluded. The remaining studies were potentially eligible and their full text was retrieved. To identify additional relevant studies, the reference lists of the included studies were checked manually. Studies were included if they met the following criteria: (1) sufficient data was reported to construct 2 × 2 tables (true positive, false positive, true negative and false negative); (2) the imaging technique was compared with a reference standard (e.g. surgery, histology, follow-up). Exclusion criteria were: (1) evaluation of imaging techniques other than the aforementioned (e.g. PET-CT, EUS-FNA, EUS-elastography); (2) imaging techniques used for treatment of patients with CP (e.g. therapeutic ERCP, EUS-guided pseudocyst drainage); (3) in vitro studies; (4) studies that included less than five patients with CP; (5) studies where no separate analysis were done for patients with CP; and (6) full-text articles that were not available or retrievable.

Data extraction and critical appraisal {#Sec5}
--------------------------------------

Data was extracted systematically from the included studies by using a structured study record form. The following study design and patient characteristics were extracted: name of the first author, country of origin, year of publication, name of journal, study design, total number of patients included, number of included patients with CP, median or mean age, the proportion of male patients, and the patient inclusion criteria.

Data was extracted regarding the imaging characteristics: type of imaging modality, scoring criteria, technical features for each modality, and reported observer experience. Also data on the reference standard was extracted, such as clinical follow-up, surgery and histology.

The methodological quality of the included articles was assessed by the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) tool \[[@CR7]\]. The QUADAS-2 tool evaluates the risk of bias in four domains (patient selection, index test, reference standard, flow and timing) and the clinical applicability in the first three domains. Signaling questions were used to help assess the risk of bias and applicability. Possible answers were 'yes', 'no' or 'unclear' in which 'yes' indicates no risk of bias. In addition the GRADE scoring system for diagnostic tests was used, which assesses the quality of evidence for each imaging modality \[[@CR8], [@CR9]\]. Although the criteria are applicable to diagnostic test accuracy, the methods are less well established compared to interventional studies \[[@CR10]\]. Two reviewers independently (YI and MAK) assessed the QUADAS-2 and the GRADE scoring system and all disagreements were resolved by reaching consensus.

Data analysis {#Sec6}
-------------

### Overall diagnostic accuracy {#Sec7}

For each included study we constructed a 2 × 2 contingency table for each imaging modality. If diagnostic accuracy was compared between different observers, mean values were calculated. Sensitivity and specificity estimates, the positive predictive value and negative predictive values, and the accuracy were calculated from the reconstructed contingency tables. We used the *I* ^2^ test with 95% confidence interval (95% CI) to quantify heterogeneity \[[@CR11]\]. Mean logit sensitivity and specificity were acquired, and the anti-logit transformation was then obtained to calculate summary estimates of sensitivity and specificity with 95% CIs. Forest plots were made to visualize the sensitivity and specificity with the 95% CIs. Summary estimates of sensitivity and specificity, including 95% CI, were obtained by using a random-effects model \[[@CR12]\]. In cases where a negative covariance between the logit sensitivity and logit specificity was obtained, summary receiver operating characteristic curve (sROC) were generated for each separate imaging modality. We used the *z* test to evaluate differences in sensitivity and specificity between the five imaging modalities. A *p* value of less than 0.05 indicated a statistically significant difference.

### Heterogeneity exploration {#Sec8}

The following factors were incorporated in the bivariate model and we evaluated the effect on the sensitivity and specificity, and cause of heterogeneity for all imaging modalities according to the QUADAS-2 tool: clear description of criteria for bias (low bias versus high bias or unclear) for (a) patient selection, (b) criteria for the index test used, (c) sufficient description and verification with the reference standard, and (d) the flow and timing.

### Head to head comparison {#Sec9}

A head to head comparison was performed in studies that compared the diagnostic accuracy of two or more imaging modalities. Heterogeneity was quantified by *I* ^2^ test, with 95% CI. The random-effects (*I* ^2^ \> 25%) and fixed effects (*I* ^2^ ≤ 25%) models were used to obtain summary estimates of sensitivity and specificity, and compared with one another by a paired *z* test.

For data analysis, Review Manager (RevMan, version 5.3. Copenhagen: The Cochrane Collaboration, 2014) and SAS (version 9.3; SAS Institute, Cary, NC) were used. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR13]\].

Results {#Sec10}
=======

Study selection {#Sec11}
---------------

The initial search resulted in 11,111 hits, of which 2988 duplicates were removed, resulting in a total of 8123 titles and abstracts that were screened for eligibility. The full text of 277 articles was retrieved; 43 of these articles fulfilled the inclusion criteria. See Appendix Table [6](#Tab6){ref-type="table"} for the excluded articles. Figure [1](#Fig1){ref-type="fig"} shows the flow chart of the search.Fig. 1Flow chart

Study and patient characteristics {#Sec12}
---------------------------------

Study characteristics, including the reference standard for the diagnosis of CP for each included study, are listed in Table [1](#Tab1){ref-type="table"}. The 43 included studies were published between 1975 and 2016; 26 studies were prospective and 23 studies were published after the year 2000. A total of 3460 patients were evaluated, of which 1242 patients were diagnosed with CP \[[@CR14]--[@CR56]\]. The age of the patients ranged from 36 to 65 years, with a median of 50% male. Criteria for selection of patients were those with suspected pancreatic disease or patients with suspected CP. Patient characteristics are depicted in Table [2](#Tab2){ref-type="table"}.Table 1Study characteristics of included studiesStudyYearCountryP/ROEModalityReference standard for CP diagnosisAdamek et al2000GermanyPNoMRCP/ERCPHistology (NA), FU (NA)Albashir et al2010USARYesEUSHistology (all)Alcaraz et al2000SpainPYesMRCPSurgery (4), ERCP (70), PTC (7)Balci et al2006USA and GermanyRNoMRCPePFT (all)Bolog et al2004RomaniaRNoMRCPSurgery (NA), ERCP (NA), FU (NA)Brand et al2000GermanyPNoEUSHistology (all)Buscail et al1995FrancePNoUS/CT/ERCP/EUSHistology (7), morphological changes (i.e. calcifications) and exocrine insufficiency (42) + FU (all)Catalano et al1998USAPNoEUSERCP + ePFT (all)Chong et al2007USARYesEUSSurgery (all)Conwell et al2007USARYesEUSePFT (all)Dramaix et al1980FrancePNoUS/CTSurgery (NA), ERCP (NA)Fusari et al2010ItalyPYesCT/MRCPBiopsy (33), histology (7)Gebel et al1985GermanyPNoUS/ERPObduction (NA), Surgery (NA), FU (NA)Giovannini et al1994FrancePNoEUSERCP (all)Glasbrenner et al2000GermanyPYesEUS/ERCPSurgery (all)Gmelin et al1981GermanyPNoUS/CT/ERCPSurgery (NA)+FU (NA)Hellerhoff et al2002GermanyPYesMRCP/sMRCPERCP (35), surgery (4), FU (56)Imdahl et al1999GermanyPYesCTHistology (42), FU (6)Kremer et al1977GermanyRNoUSClinical diagnosis (338), ERCP, surgery, ePFT, angiography (NA)Lammer et al1980GermanyRNoERCP/CTSurgery (31), angiography (16), clinical diagnosis (60)Lawson et al1978USARYesERCP/USSurgery (25), FU (50)Lees et al1979UKPNoUSSurgery (36), ERCP (46)Lin et al1989TaiwanRNoUS/EUSHistology (26), CT (4), surgery+ERCP (3)Nattermann et al1993GermanyPNoEUSERCP (94), FU (20)Pamos et al1998SpainPYesMRCPERCP (all)Parsi et al2008USARYesERCPFU (all)Pistolesi et al1981ItalyPNoCTSurgery (all)Pungpapong et al2007USAPYesEUSClinical history, lab data, ERCP/CT/MRI and/or surgical pathology (all)Pungpapong et al2007USAPYesMRCP/EUSERCP (48), surgery (9), FU (57)Rudowicz-Pietruszewska et al2002PolandPNoMRCPERCP (all)Sai et al2008JapanPYessMRCPERCP (all)Savarino et al1980ItalyRNoCTSurgery (NA), calcifications (NA), clinical and lab data (NA)Scarabino et al1989ItalyRNoERCP, US, CTCombination of CT, US and ERCP (all)Schlaudraff et al2008USA and GermanyPYesMRCP/sMRCPClinical history, laboratory, radiology (≥2 methods) (all)Stevens et al2009USAPYesEUSePFT (all)Sverko et al2011CroatiaRNoMRCPHistology (all)Swobodnik et al1983GermanyPNoUS/CT/ERCPFU (59), surgery (22)Tox et al2007GermanyRYesEUSSurgery (79), FU (92)Trikudanathan et al2016USARYESEUSHistology (all)Triller et al1975SwitzerlandPNoERCPSurgery (14), autopsy (1), FU (9)Wiersema et al1993USAPNoEUS/ERCPFU (51), ePFT (16)Zhang et al2003USARNoMRCPUS (12), CT (11), ERCP (6)Zuccaro et al2009USARNoMRCP/sMRCPePFT (all)*P* prospective, *R* retrospective, *OE* observer experience reported, *PTC* percutaneous transhepatic cholangiogram, *ePFT* endoscopic pancreatic function test, *FU* follow-up, *NA* not available Table 2Patient characteristics of included studiesStudyNr ptsAgeMale (%)Nr pts CPPatient selectionAdamek et al1245561%57Suspected pancreatic mass (clinical presentation, lab, US)Albashir et al2343\*57%19Suspected chronic pancreatitis (clinical presentation)Alcaraz et al8165\*\*31%8Suspected pancreatobiliary disease (clinical presentation, US)Balci et al3048\*17%11Suspected early CP (clinical presentation)Bolog et al10357\*43%15Suspected pancreatobiliary disease (US/CT or clinical presentation)Brand et al11561\*59%24Suspected focal pancreatic lesion (US/CT/ERCP or lab/tumour markers)Buscail et al6250\*79%44Suspected chronic pancreatitis (clinical presentation, lab, imaging)Catalano et al8051\*40%38Non-alcoholic recurrent acute pancreatitis (3--11 episodes)Chong et al7145\*46%64Suspected chronic pancreatitis (clinical presentation)Conwell et al5644\*45%38Suspected chronic pancreatitis (clinical presentation)Dramaix et al5052\*66%18Suspected pancreatic disease (clinical presentation)Fusari et al4062\*55%8Suspected pancreatic mass (clinical presentation and US)Gebel et alUS: 56, ERP: 45NANAUS: 22, ERP: 16Suspected pancreatic disease (clinical presentation)Giovannini et al26NANA17Suspected pancreatobiliary disease (clinical presentation, imaging/lab)Glasbrenner et al85NANA41Suspected pancreatic mass (clinical presentation, US/CT)Gmelin et al4154\*68%19Suspected pancreatic disease (clinical presentation)Hellerhoff et al95NANA26Suspected pancreatic disease (clinical presentation)Imdahl et al4858\*60%12Suspected pancreatic disease (clinical presentation)Kremer et al446NANA61Suspected pancreatic disease (clinical presentation)Lammer et al107NANA39Suspected pancreatic disease (clinical presentation)Lawson et al75NANA26Suspected pancreatic disease (clinical presentation)Lees et al98NANA20Suspected pancreatic disease (clinical presentation)Lin et al3347\*58%7Suspected pancreatic disease (clinical presentation)Nattermann et al11453\*67%51Suspected pancreatic disease (clinical presentation)Pamos et al4164\*59%5Suspected pancreatobiliary disease (clinical presentation)Parsi et al3546\*\*46%24Suspected chronic pancreatitis (clinical presentation)Pistolesi et al100NANA31Suspected pancreatic disease (clinical presentation)Pungpapong et al7950\*\*35%38Suspected chronic pancreatitis (clinical presentation)Pungpapong et al9955\*\*41%40Suspected chronic pancreatitis (clinical presentation)Rudowicz-Pietruszewska et al8852\*64%9Suspected pancreatobiliary disease (clinical presentation, lab, US/CT)Sai et al2836\*NA16Mild chronic pancreatitis (ERCP)Savarino et al10847\*\*67%59Suspected pancreatic disease (clinical presentation)Scarabino et al6344\*\*63%12Suspected of biliopancreatic disease (clinical presentation)Schlaudraff et al62NANA9Suspected chronic pancreatitis (clinical presentation)Stevens et al100NA38%41Suspected chronic pancreatitis (clinical presentation)Sverko et al2944\*\*52%14Suspected pancreatic disease (clinical presentation)Swobodnik et al8149\*52%27Suspected pancreatic disease (clinical presentation)Tox et al17161\*NA65Suspected pancreatic disease (clinical presentation)Trikudanathan et al6839\*18%56Total pancreatectomy for non-calcific chronic pancreatitisTriller et al2452\*83%11Suspected pancreatobiliary disease (clinical presentation)Wiersema et al6745\*20%30Suspected pancreatobiliary disease (clinical presentation)Zhang et al4450\*30%24Suspected early or mild chronic pancreatitis (clinical presentation, US/CT/ERCP)Zuccaro et al6943\*35%28Suspected chronic pancreatitis (clinical presentation)*NA* not available\*Mean\*\*Median

The risk of bias, assessed by QUADAS-2, was low in 28% of the studies and high in 19% of the studies. The concerns about applicability were low in 30% of the studies and high in 40% of the studies. The QUADAS-2 characteristics for each domain are depicted in Fig. [2](#Fig2){ref-type="fig"} and outlined for each study in Appendix Table [7](#Tab7){ref-type="table"}. The quality of evidence for all five imaging modalities according to the GRADE scoring system was very low. The GRADE scores for each imaging modality and characteristics for each study are outlined in Appendix Tables [8](#Tab8){ref-type="table"} and [9](#Tab9){ref-type="table"}.Fig. 2Summary of study quality (QUADAS-2)

EUS was the most frequently evaluated imaging modality; 16 studies including 1249 patients \[[@CR15], [@CR19]--[@CR23], [@CR27], [@CR28], [@CR36], [@CR37], [@CR41], [@CR42], [@CR48], [@CR51], [@CR53], [@CR56]\]. ERCP was studied in 11 studies including 742 patients \[[@CR14], [@CR20], [@CR26], [@CR28], [@CR29], [@CR33], [@CR34], [@CR39], [@CR46], [@CR50], [@CR52]\]; MRCP, including secretin-enhanced MRCP, was evaluated in 14 studies including 933 patients \[[@CR14], [@CR16]--[@CR18], [@CR25], [@CR30], [@CR38], [@CR42]--[@CR44], [@CR47], [@CR49], [@CR54], [@CR55]\]; CT in 10 studies including 700 patients \[[@CR20], [@CR24], [@CR25], [@CR29], [@CR31], [@CR33], [@CR40], [@CR45], [@CR46], [@CR50]\] and abdominal US in 10 studies which included 1005 patients \[[@CR20], [@CR24], [@CR26], [@CR29], [@CR32], [@CR34]--[@CR36], [@CR46], [@CR50]\]. The imaging characteristics for each study and modality in an individual study are listed in Appendix Table [11](#Tab11){ref-type="table"}. Three of the 43 articles reported about complications of the imaging modality used; these were complications related to ERCP (being post-ERCP pancreatitis) with a mean complication rate of 4% \[[@CR14], [@CR20], [@CR28]\].

Overall diagnostic accuracy {#Sec13}
---------------------------

Analyses for summary estimates of sensitivity and specificity were done for EUS, ERCP, MRI, CT and US (Table [3](#Tab3){ref-type="table"}). Figures [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} show sensitivity and specificity of individual studies in forest plots and in receiver operator curves (ROC), respectively. A negative covariance between the logit sensitivity and logit specificity was not obtained; therefore, no sROC for MRI and US could be drawn. The summary estimate of sensitivity for EUS, ERCP, MRCP, CT and US was 81%, 82%, 78%, 75% and 67%, respectively. The summary estimate of specificity for EUS, ERCP, MRCP, CT and US was 90%, 94%, 96%, 91% and 98%, respectively. Sensitivity of ERCP was significant higher than sensitivity of US (*p* = 0.018). Other pairwise comparisons of sensitivity between imaging modalities revealed no significant difference. Specificity did not differ significantly among all modalities (Table [3](#Tab3){ref-type="table"}). Sensitivity and specificity values for each study are listed in Appendix Table [10](#Tab10){ref-type="table"}.Table 3Estimated overall sensitivity, specificity and heterogeneity according to imaging modalityModality*N* studies*N* patientsSensitivity (95% CI)Specificity (95% CI)Heterogeneity (*I* ^2^)EUS16124981% (70--89%)90% (82--95%)82%/73%ERCP1174282% (76--87%)94% (87--98%)39%/67%MRCP1493378% (69--85%)96% (90--98%)59%/65%CT1070075% (66--83%)91% (81--96%)50%/71%US10100567% (53--78%)98% (89--100%)40%/93%Random effects model Fig. 3Forest plot for sensitivity and specificity Fig. 4Receiver operator curves (ROC)

Heterogeneity exploration {#Sec14}
-------------------------

The bivariate model for heterogeneity exploration showed that the factor 'flow and timing' was significantly associated with a higher sensitivity of US (*p* = 0.01). 'Description and verification with the reference standard' was significantly associated with a higher specificity for MRCP (*p* = 0.0002).

Head to head comparison {#Sec15}
-----------------------

Six head to head comparisons were performed (Table [4](#Tab4){ref-type="table"}). The specificity of ERCP and EUS, and the sensitivity of ERCP, EUS and CT in the summary estimates of the head to head studies were significantly higher as compared with US.Table 4Head to head comparisonComparison*N* studies*N* patientsModalitySensitivity (95% CI)Specificity (95% CI)US vs ERCP^a^6423US57% (49--65%)94% (74--99%)ERCP78% (71--85%)98% (89--100%)US vs CT^b^5297US58% (49--66%)77% (71--83%)CT77% (68--83%)82% (74--88%)CT vs ERCP^b^5354CT75% (67--82%)86% (81--90%)ERCP84% (77--89%)90% (85--93%)EUS vs ERCP^b^3214EUS88% (80--93%)85% (76--91%)ERCP86% (78--91%)92% (85--96%)MRCP vs sMRCP^b^3226MRCP62% (49--73%)94% (89--97%)sMRCP68% (56--79%)91% (85--94%)EUS vs US^b^295EUS90% (82--98%)100%US63% (49--76%)91% (82--99%)Sensitivity: US vs ERCP (*p* \< 0.001), US vs CT (*p* = 0.002), EUS vs US (*p* = 0.001)Specificity: US vs ERCP (*p* = 0.003), EUS vs US (*p* = 0.04)^a^Random effects model^b^Fixed effects model

The head to head comparison of US versus ERCP comparison yields a sensitivity of 57% (49--65%) versus 78% (71--85%) (*p* \< 0.001); and a specificity of 94% (74--99%) versus 98% (89--100%) (*p* = 0.003), respectively \[[@CR20], [@CR26], [@CR29], [@CR34], [@CR46], [@CR50]\]. The comparison between US and CT yields a sensitivity of 58% (49--66%) and 77% (68--83%) (*p* = 0.002), respectively \[[@CR20], [@CR24], [@CR29], [@CR46], [@CR50]\]. And finally, the comparison of EUS versus US comparison yields a sensitivity of 90% (82--98%) versus 63% (49--76%) (*p* = 0.001); and a specificity of 100% versus 91% (82--99%) (*p* = 0.04), respectively \[[@CR20], [@CR36]\]. There were no significant differences in the sensitivity and specificity estimates between ERCP and EUS \[[@CR20], [@CR28], [@CR53]\], MRCP and sMRCP \[[@CR30], [@CR47], [@CR55]\] or ERCP and CT \[[@CR20], [@CR29], [@CR33], [@CR46], [@CR50]\]. The heterogeneity (*I* ^2^) between US and ERCP (\>25%) was higher (\>25%) than in the other comparisons (*I* ^2^ ≤ 25%).

Discussion {#Sec16}
==========

EUS, ERCP, MRI and CT all have comparable high diagnostic accuracy in the initial diagnosis of chronic pancreatitis. EUS and ERCP are outperformers and US has the lowest accuracy. The choice of imaging modality can therefore be made on the basis of invasiveness, local availability, experience and costs.

Several recent guidelines \[[@CR57]--[@CR59]\] advocate the use of EUS, MRCP or CT for the diagnosis of CP, although summary estimates of their accuracy, thus far, were lacking. There is one guideline from Germany on CP that has reported sensitivity and specificity regarding EUS, ERCP, MRCP and US, although not for CT \[[@CR60]\]. In this guideline 14 studies were selected, reporting ranges rather than pooling the data on sensitivity and specificity estimates. This method resulted in results slightly different from those in the present meta-analyses. For example the guideline reports a sensitivity of 70--80% for ERCP and 88% for MRI versus summary estimates of 82% and 78%, respectively, in the present meta-analyses. The European Society of Radiology (ESR) is developing the ESR iGuide, a clinical decision support system for European imaging referral guidelines, covering various clinical scenarios, indications and recommendations ([www.esriguide.org](http://www.esriguide.org/)) \[[@CR61]--[@CR63]\]. The results from the present systematic review may be useful to incorporate in that system.

We excluded three studies where sensitivity and specificity data were provided, but it was not possible to extract sufficient data to produce 2 × 2 tables and calculate the diagnostic accuracy values, because only the sensitivity and specificity estimates were given \[[@CR64]--[@CR66]\]. In the study by Wang et al., estimates of sensitivity and specificity for EUS, ERCP and US were in line with the present results; the sensitivity of MR imaging and CT, however, were much lower (66% and 61%) \[[@CR66]\]. The studies by Clave et al. and Orti et al. showed a lower sensitivity of ERCP (62% and 70%, respectively) compared to present results (82%) \[[@CR64], [@CR65]\].

The risk of missing important studies was minimized by performing a search in four major databases by two reviewers independently, without setting any restrictions for language and publication date. However, this systematic review has some limitations. The heterogeneity of the pooled studies was moderate to high in all analyses (between 39% and 93%). However, in the head to head comparison analyses, the heterogeneity was low in most comparisons (\<25%). Furthermore, the heterogeneity of the reference standards used in the studies could have influenced individual study results. Surgery, histology and long-term follow-up of patients are reliable methods. Some reference standards, such as the use of endoscopic pancreatic function test (ePFT) for establishing the diagnosis of CP, could have resulted in under- or overestimation of the sensitivity and specificity. In addition, the diagnosis of CP and the criteria used are different in different stages of the disease (e.g. absence of calcifications in the early phase of the disease). Another limitation was that our analyses included imaging studies and imaging protocols performed over the last 40 years in different centres with inherent variations in techniques and equipment. Especially in the last decade the quality of some imaging modalities (e.g. MRCP and CT) has improved considerably. Also there were concerns about the quality of the available evidence, as assessed by QUADAS-2 and the GRADE scoring system.

The highest scores for accuracy in the diagnosis of CP were found for EUS and ERCP, but these are invasive techniques. ERCP has a relatively high risk of complications, such as post-ERCP pancreatitis (1.6--15.7%, mean complication rate of 4%) and is nowadays only used for therapeutic purposes (e.g. stenting of pancreatic duct) \[[@CR67]--[@CR69]\]. To date, diagnostic ERCP is largely replaced by EUS and the cross-sectional imaging modalities CT and MRCP.

It has been suggested that CT is better in detecting parenchymal calcifications and intraductal calcifications compared to MRCP \[[@CR70]--[@CR73]\]. On the other hand, MRCP is more often able to detect significant abnormalities of the pancreatic duct (e.g. PD dilatation and strictures) and slight changes of the pancreatic parenchyma and side branches, which can be attributed to early signs CP (i.e. atrophy, side branch ectasia) compared to CT \[[@CR74]\]. Early diagnosis can also lead to a timely start of treatment, which has been associated with improved long-term outcome \[[@CR75]\]. Nevertheless, for very early CP this association needs to be established in further research, such as the ESCAPE trial, evaluating the effect of early intervention in patients with CP \[[@CR76]\]. As diagnostic sensitivity of CT and MRCP is not significantly lower than that of ERCP and EUS, and specificity is comparable, non-invasive modalities except for US are a likely first choice in patients with suspected pancreatic disease including chronic pancreatitis.

APPENDIX {#Sec17}
========

Table [5](#Tab5){ref-type="table"} Table 5Search termsMeSH termsAll FieldsChronic pancreatitisPancreatitis, chronic \[MeSH\]Chronic pancreatitis \[All Fields\]ANDEUSEndosonography \[MeSH\]EUS \[All Fields\]ORERCPCholangiopancreatography, Endoscopic Retrograde \[MeSH\]Endoscopic Retrograde Cholangiopancreatograp\* \[All Fields\] OR ERCP \[All Fields\]ORMRCPMagnetic Resonance Imaging \[MeSH\] OR Cholangiopancreatography, Magnetic Resonance \[MeSH\]Magnetic resonance imaging \[All Fields\] OR MRI \[All Fields\] OR MRCP \[All Fields\] OR Magnetic Resonance Cholangio\* \[All Fields\]ORsMRCPMagnetic Resonance Imaging \[All Fields\] AND secretin \[All Fields\] OR sMRI \[All Fields\]ORCTTomography, X-Ray Computed \[MeSH\](Tomography \[All Fields\] AND x-ray \[All Fields\] AND computed \[All Fields\]) OR Computed Tomography \[All Fields\]) OR CT scan\* \[All Fields\]ORUSUltrasonography \[MeSH\]Ultrasonogra\* \[All Fields\] OR ultrasound \[All Fields\]*MeSH* Medical Subject Headings

Table [6](#Tab6){ref-type="table"} Table 6Excluded articles based on full textAuthorYearJournalReason for exclusionBorsukov et al2001Ross Gastroenterol ZhArticle not availableDiad\'kin et al2013Vestnik rentgenologii i radiologiiArticle not availableDotsenko et al1985Vrach DeloArticle not availableRosch et al1989Z GastroenterologieArticle not availableSuzdalev et al1992Likars\'ka spravaArticle not availableAgarwal et al2008GIEExclusive patient groupBrailski et al1989Vutr BolesExclusive patient groupBrailski et al1984Vutr BolesExclusive patient groupBrimiene et al2011MedicinaExclusive patient groupCarlucci et al1989HPB SurgeryExclusive patient groupChowdhury et al2005PancreasExclusive patient groupCotton et al1980RadiologyExclusive patient groupDelMaschio et al1991RadiologyExclusive patient groupErturk et al2006Am J GastroenterolExclusive patient groupFrick et al1982Gastrointest RadExclusive patient groupGheonea et al2013BMC GastroenterologyExclusive patient groupGoodale et al1981Ann SurgExclusive patient groupHanninen et al2002RadiologyExclusive patient groupHatano et al1998Nippon rinsho JExclusive patient groupHocke et al2008Dtsch Med WochenschrExclusive patient groupHocke et al2006WJGExclusive patient groupHocke et al2012Z GastroenterologieExclusive patient groupHuang et al2011J Dig disExclusive patient groupImbriaco et al2006Radiol MedExclusive patient groupKawai et al2012Eur J RadExclusive patient groupKim et al2007J MRIExclusive patient groupKursawa et al1991Radiol DiagnExclusive patient groupLu et al2013Acad J Sec Mil Med UniversityExclusive patient groupLutz et al1975Klin WschrExclusive patient groupMorris-Stiff et al2009J PancreasExclusive patient groupPapp et al1978Wiener klin WchnschrftExclusive patient groupPomerri et al1991Radiologia MedExclusive patient groupRosch et al2000Am J GastroenterolExclusive patient groupSandrasegaran et al2013AJRExclusive patient groupSendler et al2000World J SurgExclusive patient groupSugumar et al2011GutExclusive patient groupTestoni et al1981Acta EndoscopicaExclusive patient groupTiushin et al2003Voprosy onkologiiExclusive patient groupVaradarajulu et al2007GIEExclusive patient groupViceconte et al1980Ann ital chirExclusive patient groupYamada et al2010Abdom ImagingExclusive patient groupZhu et al2013PLOS oneExclusive patient groupBhutani et al2009PancreasIn vitroAkisik et al2013AJRNo diagnostic values for CPAlempijević et al2005Vojnosanit PreglNo diagnostic values for CPAlpern et al1985RadiologyNo diagnostic values for CPArdelean et al2014Med UltrasonNo diagnostic values for CPArdengh et al2011GIENo diagnostic values for CPAscunce et al2010Surg EndNo diagnostic values for CPBaert et al1977RadiologeNo diagnostic values for CPBalci et al2010J MRINo diagnostic values for CPBeliao et al2012Eur J RadNo diagnostic values for CPBender et al1999Invest RadNo diagnostic values for CPBhatt et al2005Indian J Rad Imag AssNo diagnostic values for CPBonanno et al1994Giorn Ital End DigNo diagnostic values for CPBruhlmann et al1976RoFoNo diagnostic values for CPCaletti et al1982British j SurgeryNo diagnostic values for CPCao1989Zhonghua yi xue za zhiNo diagnostic values for CPCappeliez et al2000RadiologyNo diagnostic values for CPChang et al2010GIENo diagnostic values for CPCohen et al2014Dig Dis SciNo diagnostic values for CPConcia et al2014Invest RadNo diagnostic values for CPDale et al1979ElectromedicaNo diagnostic values for CPDas et al2008GIENo diagnostic values for CPDelbeke et al1999J Nucl MedNo diagnostic values for CPDite et al1982Vnitrni LekarstviNo diagnostic values for CPDronamraju et al2016Ann GastroenterolNo diagnostic values for CPD'Souza et al2015Dig Dis SciNo diagnostic values for CPEitner et al1979Dtsch Zeitschr Verdauungs- und StoffwechselkrankheitenNo diagnostic values for CPEloubeidi et al2013PancreasNo diagnostic values for CPErgul et al2014Rev Esp Med Nucl Im MolNo diagnostic values for CPFerrucci et al1979RadiologyNo diagnostic values for CPFoley et al1980Gastrointest RadNo diagnostic values for CPFontana et al1976GutNo diagnostic values for CPFoster et al1984BMJNo diagnostic values for CPGardner et al2014PancreasNo diagnostic values for CPGincul et al2014EndoscopyNo diagnostic values for CPGowland et al1981LancetNo diagnostic values for CPGrant et al1981J Am Osteopathic AssNo diagnostic values for CPHarada et al1977Gastroenterologica JapNo diagnostic values for CPHe et al2014PancreasNo diagnostic values for CPHoki et al2009J GastroenterolNo diagnostic values for CPHollerbach et al1994Med KlinikNo diagnostic values for CPHorii et al1982Jap J GastroenterolNo diagnostic values for CPJohnson et al1999RadiologyNo diagnostic values for CPJones et al1988Clin RadiolNo diagnostic values for CPKamisawa et al2007J GastroenterolNo diagnostic values for CPKersting et al2009GastroenterologyNo diagnostic values for CPKitano et al2004GutNo diagnostic values for CPLaghi et al1998ChirurgiaNo diagnostic values for CPLeblanc et al2014PancreasNo diagnostic values for CPLeblanc et al2014PancreasNo diagnostic values for CPLi et al2001Zhongguo yi xue ke xueNo diagnostic values for CPLoginov et al1976Sovetskaya MeditsinaNo diagnostic values for CPLopez et al2002RadiologyNo diagnostic values for CPManfredi2000RadiologyNo diagnostic values for CPModder et al1979RoFoNo diagnostic values for CPMontori et al1979Min Diet GastroentNo diagnostic values for CPNapoleon et al2010EndoscopyNo diagnostic values for CPNovis et al1976S Afr Med JNo diagnostic values for CPOhtsubo et al2008Gastroenterolog EndoscopyNo diagnostic values for CPOrlikov et al2007Ter ArkhNo diagnostic values for CPPark et al2008The Korean J GastroenterNo diagnostic values for CPPetersein et al2002RoFoNo diagnostic values for CPPezzelli et al2013PancreasNo diagnostic values for CPPomerri et al1987Radiologia MedNo diagnostic values for CPRickes et al2002Scand J GastroenterolNo diagnostic values for CPRosenberger et al1979MMWNo diagnostic values for CPRussell et al1978GutNo diagnostic values for CPSahai et al1998GIENo diagnostic values for CPSainani et al2009AJGNo diagnostic values for CPSica et al2002J MRINo diagnostic values for CPSica et al1999RadiologyNo diagnostic values for CPSongur et al2000Digest EndoscopyNo diagnostic values for CPStevens et al2010WJGNo diagnostic values for CPStruve et al1982Diagnostik & IntensivtherapieNo diagnostic values for CPSun et al2010Acad J Sec Mil Med UniversityNo diagnostic values for CPTamura et al2006RadiologyNo diagnostic values for CPTellez-Avila et al2014WJGNo diagnostic values for CPTirkes et al2016J MRINo diagnostic values for CPTrikudanathan et al2015Am J GastroenterolNo diagnostic values for CPTripathi et al2002Indian J GastroenterolNo diagnostic values for CPTympner et al1979Leber Magen DarmNo diagnostic values for CPTympner et al1977Verhand Dtschen Gesellschaft fur Innere MedizinNo diagnostic values for CPUskudar et al2009PancreasNo diagnostic values for CPValentini et al1981EndoscopyNo diagnostic values for CPVarghese et al2002Clin RadiolNo diagnostic values for CPWang et al2013WJGNo diagnostic values for CPWierzbicka-Paczos et al1998Gastroenterologia PolskaNo diagnostic values for CPWierzbicka-Paczos et al1999Polski Merk LekNo diagnostic values for CPWill et al2010Ultraschall MedNo diagnostic values for CPZaheer et al2014Eur J RadNo diagnostic values for CPBian et al2014Chin J RadiolNo reference standardBraganza et al1978Clin RadiolNo reference standardGillams et al2007Eur J RadNo reference standardHelmberger et al2000RoFoNo reference standardHernandez Garces et al2004J PancreasNo reference standardHo et al2006Clin Gastroenterol HepNo reference standardKalmar et al1984Southern Medical JNo reference standardKalmin et al2011Can J GastroenterolNo reference standardKaufman et al1989GIENo reference standardKumon et al2012GIENo reference standardManfredi et al1998La Rad MedicaNo reference standardNovotny et al2000Bratisl Lek ListyNo reference standardPonette et al1976Acta Gastro-Enterol BelgicaNo reference standardSanyal et al2012AJRNo reference standardYoshimoto et al1980Jap J GastroenterolNo reference standardGrossjohann et al2010Scand J GastroenterolNot enough patientsSood et al1992Indian J GastroenterolNot enough patientsZhi et al2002Chin J Digestive DisNot enough patientsZhong et al2003WJGNot enough patientsAinsworth et al2003EndoscopyOnly sensitivity reportedBastid et al1995J d\'Echographie et de Med par UltrasonsOnly sensitivity reportedCampisi et al2009Clin RadiolOnly sensitivity reportedDancygier et al1986Scand J GastroenterolOnly sensitivity reportedGiday et al2011J Gastr HepOnly sensitivity reportedGuarita et al1982AMBOnly sensitivity reportedGuo et al2003Chin J Digestive DisOnly sensitivity reportedKahl et al2002GIEOnly sensitivity reportedKim et al2001AJROnly sensitivity reportedKolmannskog et al1981Acta RadiologicaOnly sensitivity reportedLackner et al1980RoFoOnly sensitivity reportedLawson1978RadiologyOnly sensitivity reportedManfredi2002RadiologyOnly sensitivity reportedMao et al2011WCJDOnly sensitivity reportedNakashio1992Acta medicaOnly sensitivity reportedNoguchi et al1985Gastroenterolog EndoscopyOnly sensitivity reportedPropp2011Vestnik khirurgii imeniOnly sensitivity reportedRossi et al1996Giorn Ital End DigOnly sensitivity reportedSahel et al1976Acta EndoscopicaOnly sensitivity reportedSeicean et al2010Ultraschall MedOnly sensitivity reportedSildiroglu1985RontgenpraxisOnly sensitivity reportedSingh et al1993Indian J Rad ImagOnly sensitivity reportedSivak et al1986Scand J GastroenterolOnly sensitivity reportedStabile Ianora et al2013Recenti Prog MedOnly sensitivity reportedStevens et al2008Dig Dis SciOnly sensitivity reportedStevens et al2010Dig Dis SciOnly sensitivity reportedTriller et al1983ComputertomographieOnly sensitivity reportedUchida et al1997Jap J Clin RadiologyOnly sensitivity reportedVitale et al2009The Am SurgeonOnly sensitivity reportedWang et al2009J Gastr HepOnly sensitivity reportedWu et al2006World Chin J DigOnly sensitivity reportedYanling et al2001Chinese J GastroenterolOnly sensitivity reportedZhou et al1993Zhonghua nei ke za zhiOnly sensitivity reportedAithal et al2002GIEOther diseaseDoust et al1976RadiologyOther diseaseEngjom et al2015Scan J GastroenterolOther diseaseHuang et al2009Acad J Sec Mil Med UniversityOther diseaseKushnir et al2011GIEOther diseaseLai et al2004EndoscopyOther diseaseLeblanc et al2014PancreasOther diseaseMatos et al2001GIEOther diseaseMosler et al2012Dig Dis SciOther diseaseNovis et al2010Rev Colegio Brasileiro CirurgOther diseaseRana et al2012J Gastr HepOther diseaseRanney et al2012GIEOther diseaseSainani et al2015PancreasOther diseaseSoto et al2005RadiologyOther diseaseAkisik et al2009RadiologyOther imaging modalityCherian et al2010HPB SurgeryOther imaging modalityGlaser et al1994Int J PancreatologyOther imaging modalityGlaser et al1989Scand J GastroenterolOther imaging modalityGlaser et al1985Ultraschall MedOther imaging modalityHocke et al2007PancreasOther imaging modalityKumon et al2010GIEOther imaging modalitySaftoiu et al2008GIEOther imaging modalitySreenarasimhaiah2008J Clin GastroenterolOther imaging modalityTummula et al2013Clin Transl GastroenterolOther imaging modalityUehara et al2011J Gastr HepOther imaging modalityAbdalla et al2012GastroenterolgyOther type of articleArsac et al1981Med Chirurgie DigestOther type of articleAshida et al2011J Gastr HepOther type of articleChvatalova et al2012PancreatologyOther type of articleCzako et al2007J GastroenterolOther type of articleGupta et al2013JIMSAOther type of articleHeverhagen et al2007RoFoOther type of articleKasugai et al1982Stomach and intestineOther type of articleKent et al2008PancreasOther type of articleMarkwardt et al1980Radiologia DiagnOther type of articleMunoz et al2010Rev Med de ChileOther type of articleMusunuri et al2015Ind J GastroenterolOther type of articleQuinn et al2012GutOther type of articleRomagnuolo et al2012GIEOther type of articleSherman et al2012GIEOther type of articleShibukawa et al2015Dig EndosOther type of articleStevens et al2008PancreasOther type of articleTakahashi et al2014AJROther type of articleTrus et al1998Probl Gen SurgOther type of articleVadrot et al1981Med Chirurgie DigestOther type of articleZaruba et al2012PancreatologyOther type of articleZhang et al2011J Gastr HepOther type of article

Table [7](#Tab7){ref-type="table"} Table 7QUADAS-2 characteristics for each studyStudyBiasApplicabilityPatient selectionIndex testReference standardFlow and timingPatient selectionIndex testReference standardAdamek et alLowLowLowLowUnclearUnclearLowAlbashir et alLowLowLowLowLowLowLowAlcaraz et alLowLowLowLowHighUnclearLowBalci et alLowLowUnclearLowLowLowUnclearBolog et alLowUnclearLowLowHighUnclearLowBrand et alLowLowLowHighHighLowLowBuscail et alLowUnclearLowLowHighUnclearLowCatalano et alUnclearLowUnclearLowLowLowLowChong et alLowLowLowLowLowLowLowConwell et alLowLowHighLowLowLowUnclearDramaix et alLowLowLowLowLowUnclearLowFusari et alUnclearLowLowLowHighLowLowGebel et alLowLowLowHighLowUnclearLowGiovannini et alUnclearUnclearLowLowHighUnclearUnclearGlasbrenner et alLowLowLowLowHighLowLowGmelin et alLowLowLowLowLowHighUnclearHellerhoff et alLowLowLowLowLowLowLowImdahl et alLowLowUnclearLowLowUnclearLowKremer et alHighUnclearUnclearHighHighUnclearLowLammer et alLowLowUnclearLowLowUnclearUnclearLawson et alLowLowUnclearLowLowLowUnclearLees et alLowLowLowHighLowHighLowLin et alHighUnclearLowLowLowUnclearLowNattermann et alUnclearLowLowLowHighUnclearLowPamos et alLowLowLowLowHighUnclearLowParsi et alLowLowLowLowLowLowLowPistolesi et alUnclearLowLowLowLowLowLowPungpapong et alLowLowLowLowLowLowLowPungpapong et alLowUnclearUnclearLowLowLowLowRudowicz Pietr-uszewska et alLowUnclearLowLowHighUnclearUnclearSai et alHighLowLowLowLowLowLowSavarino et alUnclearLowLowLowLowLowLowScarabino et alLowUnclearUnclearLowHighUnclearUnclearSchlaudraff et alLowUnclearLowLowLowLowLowStevens et alLowLowUnclearLowLowLowUnclearSverko et alUnclearUnclearLowLowLowUnclearLowSwobodnik et alLowLowLowLowLowLowLowTox et alLowUnclearUnclearLowLowLowLowTrikudanathan et alUnclearLowUnclearLowHighLowLowTriller et alUnclearLowUnclearLowUnclearUnclearLowWiersema et alUnclearLowUnclearLowHighLowUnclearZhang et alHighUnclearHighLowLowUnclearHighZuccaro et alUnclearLowUnclearLowLowLowUnclear

Table [8](#Tab8){ref-type="table"} Table 8GRADE scoring systemEUSOutcome№ of studies (№ of patients)Study designFactors that may decrease quality of evidenceEffect per 1000 patients testedQuality of evidenceRisk of biasIndirectnessInconsistencyImprecisionPublication biasPre-test probability of 47.2%True positives16 (1249)Cohort & case-controlSerious ^a^Serious ^b^Very serious ^c^Very serious ^d^NA387 (335 to 425)⨁◯◯◯ VERY LOWFalse negatives85 (47 to 137)True negatives16 (1249)Cohort & case-controlSerious ^a^Serious ^b^Serious ^c^Serious ^d^NA480 (438 to 502)⨁◯◯◯ VERY LOWFalse positives48 (26 to 90)ERCPOutcome№ of studies (№ of patients)Study designFactors that may decrease quality of evidenceEffect per 1000 patients testedQuality of evidenceRisk of biasIndirectnessInconsistencyImprecisionPublication biasPre-test probability of 42.6%True positives11 (742)Cohort & case-controlNot serious ^e^Serious ^f^Serious ^g^Serious ^h^NA349 (324 to 371)⨁◯◯◯ Very lowFalse negatives77 (55 to 102)True negatives11 (742)Cohort & case-controlNot serious ^e^Serious ^f^Serious ^g^Serious ^h^NA540 (499 to 563)⨁◯◯◯ Very lowFalse positives34 (11 to 75)MRCPOutcome№ of studies (№ of patients)Study designFactors that may decrease quality of evidenceEffect per 1000 patients testedQuality of evidenceRisk of biasIndirectnessInconsistencyImprecisionPublication biasPre-test probability of 28.9%True positives14 (933)Cohort & case-control-type studiesSerious ^i^Serious ^j^Serious ^k^Very serious ^l^NA225 (199 to 246)⨁◯◯◯ Very lowFalse negatives64 (43 to 90)True negatives14 (933)Cohort & case-control-type studiesSerious ^i^Serious ^j^Serious ^k^Not serious ^l^NA683 (640 to 697)⨁◯◯◯ Very lowFalse positives28 (14 to 71)CTOutcome№ of studies (№ of patients)Study designFactors that may decrease quality of evidenceEffect per 1000 patients testedQuality of evidenceRisk of biasIndirectnessInconsistencyImprecisionPublication biasPre-test probability of 38.4%True positives10 (700)Cohort & case-controlSerious ^m^Serious ^n^Serious ^o^Very serious ^p^NA288 (253 to 319)⨁◯◯◯ Very lowFalse negatives96 (65 to 131)True negatives10 (700)Cohort & case-controlSerious ^m^Serious ^n^Serious ^o^Serious ^p^NA561 (499 to 591)⨁◯◯◯ Very lowFalse positives55 (25 to 117)USOutcome№ of studies (№ of patients)Study designFactors that may decrease quality of evidenceEffect per 1000 patients testedQuality of evidenceRisk of biasIndirectnessInconsistencyImprecisionPublication biaspre-test probability of 25.7%True positives10 (1005)Cohort & case-controlSerious ^q^Serious ^r^Serious ^s^Very serious ^t^NA172 (136 to 200)⨁◯◯◯ Very lowFalse negatives85 (57 to 121)True negatives10 (1005)Cohort & case-controlSerious ^q^Serious ^r^Very serious ^s^Serious ^t^NA728 (661 to 743)⨁◯◯◯ Very lowFalse positives15 (0 to 82)*NA* not available^a^Risk of bias: based on QUADAS-2 risk of bias; 7 studies not serious, 9 studies serious^b^Indirectness: based on QUADAS-2 applicability; 7 studies not serious, 9 studies serious^c^Inconsistency: based on heterogeneity and visual inspection CIs^d^Imprecision: based on study numbers and CIs of summary estimate (CIs 0--10 = not serious, 11--15 = serious, more than 15 = very serious)^e^Based on QUADAS-2 risk of bias: 8 studies not serious, 3 studies serious^f^Based on QUADAS-2 applicability: 6 studies not serious, 5 studies serious^g^Based on heterogeneity and visual inspection CIs^h^Based on study numbers and CIs of summary estimate (CIs 0--10 = not serious, 11--15 = serious, more than 15 = very serious)^i^Risk of bias: based on QUADAS-2 risk of bias; 7 studies not serious, 5 studies serious, 1 study very serious^j^Indirectness: based on QUADAS-2 applicability; 6 studies not serious, 8 studies serious^k^Inconsistency: based on heterogeneity and visual inspection CIs^l^Imprecision: based on study numbers and CIs of summary estimate (CIs 0--10 = not serious, 11--15 = serious, more than 15 = very serious)^m^Risk of bias: based on QUADAS-2 risk of bias; 5 studies not serious, 5 studies serious^n^Indirectness: based on QUADAS-2 applicability; 6 studies not serious, 4 studies serious^o^Inconsistency: based on heterogeneity and visual inspection CIs^p^Imprecision: based on study numbers and CIs of summary estimate (CIs 0--10 = not serious, 11--15 = serious, more than 15 = very serious)^q^Risk of bias: based on QUADAS-2 risk of bias; 6 studies not serious, 3 studies serious, 1 study very serious^r^Indirectness: based on QUADAS-2 applicability; 5 studies not serious, 5 studies serious^s^Inconsistency: based on heterogeneity and visual inspection CIs^t^Imprecision: based on study numbers and CIs of summary estimate (CIs 0--10 = not serious, 11--15 = serious, more than 15 = very serious)

Table [9](#Tab9){ref-type="table"} Table 9GRADE characteristics for each studyModalityName first authorRisk of biasIndirectnessInconsistencyImprecisionPublication biasEUSAlbashir et alLowLowSensitivity: very serious Specificity: seriousSensitivity: very serious Specificity: seriousNot assessedBrand et alSeriousSeriousBuscail et alSeriousSeriousCatalano et alLowLowChong et alLowLowConwell et alSeriousSeriousGiovannini et alSeriousSeriousGlasbrenner et alLowLowLin et alSeriousSeriousNattermann et alLowSeriousPungpapong et alLowLowPungpapong et alLowLowStevens et alSeriousSeriousTox et alSeriousLowTrikudanathan et alSeriousSeriousWiersema et alSeriousSeriousERCPAdamek et alLowLowSensitivity: serious Specificity: seriousSensitivity: serious Specificity: seriousNot assessedBuscail et alLowSeriousGebel et alLowLowGlasbrenner et alLowLowGmelin et alLowSeriousLammer et alSeriousSeriousLawson et alLowLowParsi et alLowLowScarabino et alSeriousSeriousSwobodnik et alLowLowTriller et alSeriousSeriousMRCPAdamek et alLowLowSensitivity: serious Specificity: seriousSensitivity: very serious Specificity: not seriousNot assessedAlcaraz et alLowSeriousBalci et alSeriousSeriousBolog et alSeriousSeriousFusari et alLowLowHellerhoff et alLowLowPamos et alLowSeriousPungpapong et alLowLowRudowicz-PietruszewskaSeriousSeriousSai et alSeriousLowSchlaudraff et alLowLowSverko et alSeriousSeriousZhang et alVery seriousSeriousZuccaro et alSeriousSeriousCTBuscail et alLowSeriousSensitivity: serious Specificity: seriousSensitivity: very serious Specificity: seriousNot assessedDramaix et alLowLowFusari et alLowLowGmelin et alLowSeriousImdahl et alSeriousLowLammer et alSeriousSeriousPistolesi et alLowLowSavarino et alSeriousLowScarabino et alSeriousSeriousSwobodnik et alLowLowUSBuscail et alLowSeriousSensitivity: serious Specificity: very seriousSensitivity: very serious Specificity: seriousNot assessedDramaix et alLowLowGebel et alLowLowGmelin et alLowSeriousKremer et alVery seriousSeriousLawson et alLowLowLees et alSeriousLowLin et alSeriousSeriousScarabino et alSeriousSeriousSwobodnik et alLowLow

Table [10](#Tab10){ref-type="table"} Table 10Diagnostic characteristics for each studyStudySensitivitySpecificityAccuracyPPVNPVTPTNFPFNAdamek et alMRCP: 88%, ERCP: 90%MRCP: 94%. ERCP: 91%MRCP: 91% ERCP: 90%MRCP: 93%, ERCP:90%MRCP: 90%, ERCP: 91%MRCP:50 ERCP: 51MRCP: 63 ERCP: 61MRCP: 4 ERCP: 6MRCP: 7 ERCP: 6Albashir et al84%100%87%100%57%16403Alcaraz et al50%99%94%80%95%47214Balci et al82%63%70%56%86%91272Bolog et al90%98%95%90%98%148621Brand et al42%96%84%71%86%1087414Buscail et alUS: 58%,CT: 75%, ERCP: 74%, EUS: 88%US: 75%, CT: 95%, ERCP: 100%, EUS: 100%US: 65%, CT: 81%, ERCP: 82%, EUS: 92%US: 87%, CT: 97%, ERCP: 100%, EUS: 100%US: 44%, CT: 61%, ERCP: 62%, EUS: 78%US: 26, CT: 33, ERC: 33, EUS: 39US: 14, CT: 17, ERCP: 18, EUS: 18US: 4, CT: 1, ERCP: 0, EUS: 0US: 18, CT: 11, ERCP: 11, EUS: 5Catalano et al84%98%91%97%87%324116Chong et al83%80%83%98%69%535111Conwell et al26%100%50%100%39%1018028Dramaix et alCT: 60%, US: 60%CT: 100% US: 95%CT: 86% US: 82%CT: 100%, US: 90%CT: 76%, US: 76%CT: 11, US: 11CT: 32, US: 30CT: 0, US: 2CT: 7, US: 7Fusari et alCT: 88%, MRI: 88%CT: 100%, MRI:100%,CT: 98%, MRI: 98%CT: 100%, MRI: 100%CT: 97%, MRI: 97%MRI: 7, CT: 7MRI: 32, CT: 32MRI: 0, CT: 0MRI: 1, CT: 1Gebel et alUS: 82%, ERP: 56%US: 97%, ERP: 97%US: 91%, ERP: 82%US:95%, ERP: 90%US: 89%, ERP: 80%US: 18, ERP: 9US: 33, ERP: 28US: 1, ERP: 1US: 4, ERP: 7Giovannini et al94%56%81%80%83%16541Glasbrenner et alEUS: 93%, ERCP: 88%EUS: 78%, ERCP: 82%EUS: 85%, ERCP: 85%EUS: 79%, ERCP: 82%EUS: 92%, ERCP: 88%EUS: 38, ERCP: 36EUS: 34, ERCP: 36EUS: 10, ERCP: 8EUS: 3, ERCP: 5Gmelin et alUS: 68%, CT: 84%, ERCP: 89%US: 100%, CT: 91%, ERCP: 91%US: 85%, CT: 89%, ERCP: 90%US: 100%, CT: 89%, ERCP: 89%US: 79%, CT: 87%, ERCP: 91%US: 13, CT: 16, ERCP: 17US: 22, CT: 20, ERCP: 20US: 0, CT: 2, ERCP: 2US: 6, CT: 3. ERCP: 2Hellerhoff et alMRI: 77%, sMRI: 89%MRI: 100%, sMRI:100%MRI 94%, sMRI: 97%MRI: 100%, sMRI: 100%MRI: 92%, sMRI: 96%MRI: 20, sMRI: 23MRI: 69, sMRI: 69MRI: 0, sMRI: 0MRI: 6, sMRI: 3Imdahl et al58%91%83%70%85%73335Kremer et al67%99%94%89%95%42378521Lammer et alERCP: 85%, CT: 64%ERCP: 97%, CT: 85%ERCP: 93%, CT: 78%ERCP: 94%, CT: 71%ERCP: 92%, CT: 81%ERCP: 33, CT: 25ERCP: 66, CT: 58ERCP: 2, CT: 10ERCP: 6, CT: 14Lawson et alUS: 38%, ERCP: 73%US: 100%, ERCP: 98%US: 79%, ERCP: 98%US: 100%, ERCP: 95%US: 75%, ERCP: 87%US: 10, ERCP: 19US: 49, ERCP: 48US: 0, ERCP: 1US: 16, ERCP: 7Lees et al100%97%98%91%100%207620Lin et alUS: 86%, EUS: 100%US: 100%, EUS: 100%US: 97%, EUS: 100%US: 100%, EUS: 100%US: 96%, EUS: 100%US: 6, EUS: 7US: 26, EUS: 26US: 0, EUS: 0US: 1, EUS: 0Nattermann et al98%57%75%65%97%5036271Pamos et al80%100%98%100%97%43601Parsi et al71%91%77%94%59%171017Pistolesi et al58%81%74%58%81%18561313Pungpapong et al71%88%80%84%77%2736511Pungpapong et alEUS: 93%, MRCP: 65%EUS: 93%, MRCP: 90%EUS: 93%, MRCP: 80%EUS: 90%, MRCP: 81%EUS: 95%, MRCP: 79%EUS: 37, MRCP: 26EUS: 55, MRCP: 53EUS: 4, MRCP: 6EUS: 3, MRCP: 14Rudowicz-Pietruszewska et al100%100%100%100%100%97900Sai et al60%79%68%77%60%10936Savarino et al90%59%76%73%83%5329206Scarabino et alERCP: 83%, US: 42%, CT: 100%ERCP: 67%, US: 34%, CT: 70%ERCP: 70%, US: 35%, CT: 76%ERCP: 37%, US: 13%, CT: 44%ERCP: 94%, US: 71%, CT: 100%ERCP: 10, US: 5, CT: 12ERCP: 34, US: 17, CT: 36ERCP: 17, US: 34, CT: 15ERCP: 2, US: 7, CT: 0Schlaudraff et alMRCP: 67%, sMRCP: 73%MRCP: 93%, sMRCP: 96%MRCP: 89%, sMRCP: 93%MRCP: 63%, sMRCP: 78%MRCP: 95%, sMRCP: 95%MRCP: 6, sMRCP: 7MRCP: 49, sMRCP: 51MRCP: 4, sMRCP: 2MRCP: 3, sMRCP: 2Stevens et alRadial: 68%, Linear: 44%Radial: 95% Linear: 95%Radial: 84% Linear: 74%Radial: 90%, Linear: 86%Radial: 81%, Linear: 71%2856313Sverko et al79%93%86%92%82%111413Swobodnik et alUS: 52%, CT: 74%, ERCP: 93%US: 100%, CT: 98%, ERCP: 100%US: 84%, CT: 90%, ERCP: 98%US: 100%, CT: 95%, ERCP: 100%US: 81%, CT: 88%, ERCP: 96%US: 14, CT: 20, ERCP: 25US: 54, CT: 53, ERCP: 54US: 0, CT: 1, ERCP: 0US: 13, CT: 7, ERCP: 2Tox et al77%75%76%66%84%50802615Trikudanathan et al61%75%63%92%29%349322Triller et al82%85%83%82%85%91122Wiersema et al80%86%84%83%84%243256Zhang et al92%75%84%81%88%221552Zuccaro et alMRCP: 46%, sMRCP: 46%MRCP:85%, sMRCP: 68%MRCP: 70%, sMRCP: 59%MRCP: 68%, sMRCP: 50%MRCP: 70%, sMRCP: 65%MRCP: 13, sMRCP: 13MRCP: 35, sMRCP: 28MRCP: 6, sMRCP: 13MRCP: 15, sMRCP: 15*PPV* positive predictive value, *NPV* negative predictive value, *TP* true positive, *TN* true negative, *FP* false positive, *FN* false negative

Table [11](#Tab11){ref-type="table"} Table 11Imaging characteristics for each studyMagnetic resonance imaging (MRI)StudyYearMagnetic fieldCoil typeContrastSecretin enhancementSequenceScoring criteriaAdamek et al20001.0 TBody coilNoNoT2Size of common bile and pancreatic duct, the nature and degree of pancreatic duct obstruction, and accuracy in diagnosing pathological findingsAlcaraz et al20001.5 TNANoNoT2 (HASTE & RARE)NABalci et al20061.5 TFour-element quadrature phased-array surface coilIVNoT1, T2Increased arterial enhancement pattern, normal gland size and normal ductal morphology (Cambridge classification)Bolog et al20041.0 TSynergy body coilNANoT1, T2NAFusari et al20101.5 TPhased-array synergy body coilOralNoT1, T21--5 score to identify pancreatic masses (definite benign = 1, probably benign = 2 etc.)Hellerhoff et al20021.5 TPhased-array synergy surface coilOralNoT2Cambridge classificationPamos et al19981.5 TBody coilNANoT2NAPungpapong et al20071.5 TPhased-array surface coilIV/OralNoT1, T2, T2 (HASTE)Presence of 1 or more of the following features: main pancreatic duct dilatation in absence of structural obstruction, dilated side branches, intraductal stones, ductal irregularity, reduced T1 signal intensity, atrophy of pancreatic parenchyma and reduced secretory response to secretin administrationRudowicz-Pietruszewska et al20020.5 TBody coilNANoT2NASchlaudraff et al20081.0 TDedicated quadrature torso phased-array coilNANoT2, T2 (HASTE)Pancreatic duct stenosis/dilatation, side branch stenosis/dilatation, pseudocysts, extrapancreatic abscess. Based on observers' judgementSverko et al20111.0 TNAIVNoT1, T2 (HASTE)NAZhang et al20031.5 TNAIVNoT1Signal intensity by gadolinium (presence of SIR less than 1.73 in the arterial phase)Zuccaro et al2009NAPhased array-torso coilIVNoT1, T2, T2 (HASTE)Mild CP: secretin-induced T2 intensity significantly reduced; side branch ectasia, mild ductal dilatation. Moderate CP: abnormal enhancement pattern on T1 after gadolinium administration. Severe CP: atrophy or diffuse/focal enlargement of the gland, calcification, chronic pseudocystsSecretin-enhanced magnetic resonance imaging (sMRI)Hellerhoff et al20021.5 TSynerge phased-array surface coilIVYesT2Cambridge classificationSai et al20081.5 TPhased-array multi coilIVYesNACambridge classificationSchlaudraff et al20081.0 TDedicated quadrature phased-array torso coilNAYesT2, T2 (HASTE)Pancreatic duct stenosis/dilatation, side branch stenosis/dilatation, pseudocysts, extrapancreatic abscess. Based on observers' judgementZuccaro et al2009NAPhased-array torso coilIVYesT1, T2, T2 (HASTE)Mild CP: secretin-induced T2 intensity significantly reduced; side branch ectasia, mild ductal dilatation. Moderate CP: abnormal enhancement pattern on T1 after gadolinium administration. Severe CP: atrophy or diffuse/focal enlargement of the gland, calcification, chronic pseudocystsUltrasonography (US)StudyYearTransducerScoring criteriaBuscail et al1995NANADramaix et al1980Unirad/Kretz combison 200NAGebel et al1985ADR 2130 Imager 2380 Sonoline 8000Duct abnormalitiesGmelin et al1981Sono fluoroskop 1, unirad model 849Criteria for PC, CP and normal pancreas were extracted from literatureKremer et al1977NARettenmaier specified examination techniqueLawson et al197813-mm diameter 3.5 Mhz/ 13 or 19-mm diameter 2.25 MhzIdentification of a mass, pseudocyst or generalized glandular enlargement with abnormal parenchymal echogenicityLees et al19792.5 MhzAppearance of pancreatic parenchyma and duct system/size and shape of the pancreas and from previous reportsLin et al1989SAL-90A 3.75 MhzNAScarabino et al1989NANASwobodnik et al1983Siemens imager 2300 linear arrayOrgan enlarged or atrophic dense structure, areas of scars or calcification (more echogenic), sonolucent areas only during acute inflammation, dilatation of the pancreatic duct system, symmetric contours, no smooth outlinesComputed tomography (CT)StudyYearScannerContrastScoring criteriaBuscail et al1995NANANADramaix et al1980OHIO nuclear - Delta Slan 50FSOral/IVNAFusari et al2010Marconi MX8000 (four-detector row)IV1--5 score to identify pancreatic masses (definite benign = 1, probably benign = 2 etc.)Gmelin et al1981NANACriteria for PC, CP and normal pancreas were extracted from literatureImdahl et al1999Somatom Plus 4 helical scannerIVNALammer et al1980EMI-5005Oral3 stadia typical for CPPistolesi et al1981Ohio-Nuclear Delta 50 scannerNAOverall enlargement of the pancreas or calcificationsSavarino et al1980EMI-5005OralParenchymal atrophy, pancreatic calcifications, pseudocysts or abscessesScarabino et al1989NANANASwobodnik et al1983General Electric CT-T8800Oral/IVAtrophy of the organ (during acute inflammation: segmental enlargement) during acute phase; segments without clear outlines, cysts or calcifications and dense structureEndoscopic ultrasonography (EUS)StudyYearScannerTransducerMHzScoring criteriaAlbashir et al2010NANANA9 features; \>4 diagnostic for CPBrand et al2000Olympus GF-UM 3/GF-UM 20/GF-UM 200RadialNAOwn criteria (increased parenchymal lobulations, calcification and/or ductal changes or focal lesion)Buscail et al1995Olympus EU-M3NA7.5/12 MHzNACatalano et al1998Olympus EU-M3/EU-M20NA7.5/12 MHzWiersema criteria (11 features), own classification systemChong et al2007Olympus EU-M20/GF-UM130/GF-UM160/GF-UC30P/GF-UC140P/GF-UCT140RadialNA9 features; \>3 diagnostic for CPConwell et al2007NANANA9 features; \>3 diagnostic for CPGiovannini et al1994Pentax FG-32-UALinearNANAGlasbrenner et al2000Olympus EU-M20Radial7.5/12 MHzWiersema criteria (11 features)Lin et al1989Olympus GF-EUM 2/GF-UM2Radial7.5 MHzNANattermann et al1993Olympus GF-UM-3/EU-M3NA7.5/12 MHzNAPungpapong et al2007Olympus GF-UE160-AL5/GF-UC140PRadial & linearNAMST criteria; \>4 features diagnostic for CPPungpapong et al2007Olympus GF-UC140P/ UCT140-AL5Linear7.5 MHzMST criteria; \>4 features diagnostic for CPStevens et al2009Olympus GF-UM-130/GF-UE-160/GF-UC-160P-OL5Radial & linearNA9 features; \>4 diagnostic for CPTox et al2007Olympus GF-UM20, Pentax EG-3620-UR/EG-3830-UTNANAOwn criteriaTrikudanathan2016OlympusLinear7.5 MHzWiersema criteria (11 features) \>4 is CPWiersema et al1993Olympus EU-M3/EU-M20NANAWiersema criteria (11 features) \>3 is CPEndoscopic retrograde cholangiopancreatography (ERCP)StudyYearTechnical featuresScoring criteriaAdamek et al2000NANABuscail et al1995NAOwn criteria (normal/moderate changes (3 abnormal side branches and normal main duct)/marked changes (side and main duct abnormalities))Gebel et al1995NADeyhle criteriaGlasbrenner et al2000OlympusCambridge classificationGmelin et al1981NACriteria according to referencesLammer et al1980Olympus JFBLoffler criteriaLawson et al1978NACriteria according to referencesParsi et al2008NACambridge classificationScarabino et al1989NANASwobodnik et al1983Olympus JFB-2/3Own criteria (variation in diameter of the main duct in the whole organ (exception: segmental pancreatitis), cystic dilatation of side branches, kinking of the duct stones in canalicular structures, distension of the main duct)Triller et al1975NANA*NA* not available
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